Calithera Biosciences Stock Forecast, Price & News

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

Is Calithera Biosciences a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Calithera Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares.
View analyst ratings for Calithera Biosciences or view top-rated stocks.

How has Calithera Biosciences' stock price been impacted by Coronavirus?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CALA stock has decreased by 84.7% and is now trading at $0.7980.
View which stocks have been most impacted by COVID-19.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a decline in short interest in November. As of November 15th, there was short interest totaling 900,900 shares, a decline of 58.9% from the October 31st total of 2,190,000 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.3% of the shares of the company are sold short.
View Calithera Biosciences' Short Interest.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Calithera Biosciences.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.08. During the same period in the previous year, the company earned ($0.32) EPS.
View Calithera Biosciences' earnings history.

What price target have analysts set for CALA?

3 brokerages have issued 12-month target prices for Calithera Biosciences' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Calithera Biosciences' share price to reach $3.67 in the next year. This suggests a possible upside of 359.5% from the stock's current price.
View analysts' price targets for Calithera Biosciences or view top-rated stocks among Wall Street analysts.

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:

• Susan M. Molineaux, President, Chief Executive Officer & Director (LinkedIn Profile)
• Stephanie Wong, Secretary, Chief Financial & Accounting Officer
• Susan B Demo, Vice President-Medical Affairs
• Francesco Parlati, Senior Vice President-Research
• Keith Orford, Chief Medical Officer (LinkedIn Profile)

Who are some of Calithera Biosciences' key competitors?

Some companies that are related to Calithera Biosciences include Pieris Pharmaceuticals (PIRS), Syros Pharmaceuticals (SYRS), eFFECTOR Therapeutics (EFTR), CymaBay Therapeutics (CBAY), Citius Pharmaceuticals (CTXR), GX Acquisition (GXGX), Immunic (IMUX), Neoleukin Therapeutics (NLTX), Matinas BioPharma (MTNB), Leap Therapeutics (LPTX), Vincerx Pharma (VINC), DURECT (DRRX), Ovid Therapeutics (OVID), Ampio Pharmaceuticals (AMPE) and Aquestive Therapeutics (AQST).
View all of CALA's competitors.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (14.31%), BVF Inc. IL (9.95%), BlackRock Inc. (3.42%), Dimensional Fund Advisors LP (1.36%), Geode Capital Management LLC (1.09%) and Assenagon Asset Management S.A. (1.02%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong and Susan Molineaux.
View institutional ownership trends for Calithera Biosciences.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, BlackRock Inc., and Goldman Sachs Group Inc..
View insider buying and selling activity for Calithera Biosciences or view top insider-selling stocks.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Assenagon Asset Management S.A., Primecap Management Co. CA, TSP Capital Management Group LLC, Two Sigma Investments LP, BVF Inc. IL, Franklin Resources Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Calithera Biosciences or or view top insider-buying stocks.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $0.80.

How much money does Calithera Biosciences make?

Calithera Biosciences has a market capitalization of $59.79 million and generates $22.25 million in revenue each year. The biotechnology company earns $-90.14 million in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does Calithera Biosciences have?

Calithera Biosciences employs 93 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is www.calithera.com.

Where are Calithera Biosciences' headquarters?

Calithera Biosciences is headquartered at 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 870-1000 or via email at [email protected].